These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

679 related articles for article (PubMed ID: 27001629)

  • 1. Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma.
    Miyawaki Y; Nakajima Y; Kawada K; Okada T; Tokairin Y; Kawano T
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27001629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
    Satake H; Tahara M; Mochizuki S; Kato K; Hara H; Yokota T; Kiyota N; Kii T; Chin K; Zenda S; Kojima T; Bando H; Yamazaki T; Iwasa S; Honma Y; Hamauchi S; Tsushima T; Ohtsu A
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):91-9. PubMed ID: 27193097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003).
    Yamasaki M; Yasuda T; Yano M; Hirao M; Kobayashi K; Fujitani K; Tamura S; Kimura Y; Miyata H; Motoori M; Shiraishi O; Makino T; Satoh T; Mori M; Doki Y
    Ann Oncol; 2017 Jan; 28(1):116-120. PubMed ID: 27687307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II study of divided-dose docetaxel, cisplatin and fluorouracil for patients with recurrent or metastatic squamous cell carcinoma of the esophagus.
    Ojima T; Nakamori M; Nakamura M; Katsuda M; Hayata K; Matsumura S; Iwahashi M; Yamaue H
    Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 26725778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus.
    Ojima T; Nakamori M; Nakamura M; Katsuda M; Hayata K; Kato T; Kitadani J; Tabata H; Takeuchi A; Iwahashi M; Yamaue H
    Anticancer Res; 2016 Feb; 36(2):829-34. PubMed ID: 26851048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence.
    Yamashita K; Hosoda K; Moriya H; Katada C; Sugawara M; Mieno H; Komori S; Katada N; Watanabe M
    Oncology; 2017; 92(4):221-228. PubMed ID: 28110330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of initial induction chemotherapy with 5-fluorouracil, cisplatin, and docetaxel (DCF) for T4 esophageal cancer: a propensity score-matched analysis.
    Makino T; Yamasaki M; Miyazaki Y; Wada N; Takahashi T; Kurokawa Y; Nakajima K; Takiguchi S; Mori M; Doki Y
    Dis Esophagus; 2018 Apr; 31(4):. PubMed ID: 29190316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis.
    Yamashita K; Katada N; Moriya H; Hosoda K; Mieno H; Katada C; Koizumi W; Hoshi K; Watanabe M
    Gen Thorac Cardiovasc Surg; 2016 Apr; 64(4):209-15. PubMed ID: 26868531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.
    Kim S; François E; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Ghiringhelli F; Parzy A; De La Fouchardiere C; Smith D; Deberne M; Spehner L; Badet N; Adotevi O; Anota A; Meurisse A; Vernerey D; Taieb J; Vendrely V; Buecher B; Borg C
    Lancet Oncol; 2018 Aug; 19(8):1094-1106. PubMed ID: 30042063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma.
    Tanaka Y; Yoshida K; Yamada A; Tanahashi T; Okumura N; Matsuhashi N; Yamaguchi K; Miyazaki T
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1143-52. PubMed ID: 26896963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma.
    Hiyoshi Y; Yoshida N; Watanabe M; Kurashige J; Baba Y; Sakamoto Y; Baba H
    World J Surg; 2017 Feb; 41(2):480-486. PubMed ID: 27637603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced cervical esophageal cancer.
    Okamoto H; Taniyama Y; Sakurai T; Heishi T; Teshima J; Sato C; Maruyama S; Ito K; Onodera Y; Konno-Kumagai T; Ishida H; Kamei T
    Esophagus; 2018 Oct; 15(4):281-285. PubMed ID: 29948480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
    Kajiura S; Hosokawa A; Yoshita H; Ueda Y; Ueda A; Mihara H; Ando T; Fujinami H; Nishikawa J; Ogawa K; Minemura M; Sugiyama T
    Am J Clin Oncol; 2016 Feb; 39(1):13-7. PubMed ID: 24322336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
    Cho H; Nishiike S; Yamamoto Y; Takenaka Y; Nakahara S; Yasui T; Hanamoto A; Inohara H
    Auris Nasus Larynx; 2015 Oct; 42(5):396-400. PubMed ID: 25721854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma.
    Sasaki K; Uchikado Y; Omoto I; Arigami T; Osako Y; Noda M; Okumura H; Maemura K; Higashi R; Yoshiura T; Natsugoe S
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):581-587. PubMed ID: 30623230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma.
    Sudarshan M; Alcindor T; Ades S; Aloraini A; van Huyse M; Asselah J; David M; Frechette D; Brisson S; Thirlwell M; Ferri L
    Ann Surg Oncol; 2015 Jan; 22(1):324-30. PubMed ID: 25023544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Pilot Trial of S-1 and Paclitaxel in Unresectable or Postoperative Recurrent Esophageal Squamous Cell Carcinoma Pretreated by Fluorouracil, Cisplatin, and Docetaxel Chemotherapy.
    Nakajima Y; Kawada K; Tokairin Y; Hoshino A; Okada T; Kawano T
    Dig Surg; 2018; 35(2):131-137. PubMed ID: 28554183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of combined docetaxel and nedaplatin chemotherapy for recurrent esophageal cancer compared with conventional chemotherapy using cisplatin and 5-fluorouracil: a retrospective study.
    Fujita Y; Hiramatsu M; Kawai M; Sumiyoshi K; Nishimura H; Tanigawa N
    Dis Esophagus; 2008; 21(6):496-501. PubMed ID: 18840134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus.
    Yamasaki M; Miyata H; Tanaka K; Shiraishi O; Motoori M; Peng YF; Yasuda T; Yano M; Shiozaki H; Mori M; Doki Y
    Oncology; 2011; 80(5-6):307-13. PubMed ID: 21778771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor/normal esophagus ratio in (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for response and prognosis stratification after neoadjuvant chemotherapy for esophageal squamous cell carcinoma.
    Izumi D; Yoshida N; Watanabe M; Shiraishi S; Ishimoto T; Kosumi K; Tokunaga R; Taki K; Higashi T; Harada K; Miyata T; Ida S; Imamura Y; Iwagami S; Baba Y; Sakamoto Y; Miyamoto Y; Yamashita Y; Baba H
    J Gastroenterol; 2016 Aug; 51(8):788-95. PubMed ID: 26671045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.